Genmab---no delivery? I hope you are not serious.
I remember that biotech bubble well.MEDX went from $6[for me] to its high of $206, trickled down to ~$170 where it split 2 for 1, and ultimately wound up about where it started. I had met Don Drakeman sometime in the mid 90s at Princeton where both of us had been invited by the Graduate College to speak to post-docs, etc on job opportunities in the real world outside academia. Investment followed thereafter. Was not smart enough to sell anywhere near the above top---I thus escaped retiring early in multi-millionaire status from MEDX and a host of other accumulated biotechs that also crashed--litigation world for me was a preoccupation then much as now. Can't complain too much.IMCL, MLNM, AMLN and a few others have been ~good as MEDX turned out to be.
Your description of Drakeman is not totally accurate, IMO, but is better applied to his ultimate successor who was CEO at time of BMY takeover.
Market Data 
Markets 
AI
